Drugs / FMP013
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04268420 Comparator | Mar 2020 → Jul 2023 | vaccinia | U.S. Army Medical Research and Development Command | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMP013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04268420 ↗ |
| Known as | Plasmodium falciparum malaria protein 013 | “First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ...” PMID 36055874 ↗ Aug 2022 |
| Modality | Vaccine | “FMP013/ALFQ malaria vaccine candidate” PMID 36055874 ↗ Aug 2022 |
| Route | Intramuscular | “Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly” PMID 36055874 ↗ Aug 2022 |